Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal ...

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare ...

Omeros ( ($OMER) ) has issued an update. On October 10, 2025, Omeros Corporation entered into an Asset Purchase and License Agreement with Novo ...

A research team has outlined how synthetic biology can accelerate discoveries in plant–microbe interactions, offering ...

The biotech is also eligible to receive up to $2.1bn in development and commercial milestone payments from Novo Nordisk, ...

Detailed price information for Dianthus Therapeutics Inc (DNTH-Q) from The Globe and Mail including charting and trades.

Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patientsReal-world evidence and long-term data reinforce VYVGART’s sustained ...

The LPGA Tour has launched the LPGA Elite Amateur Pathway (LEAP), a program providing top amateur female golfers a new path to LPGA Tour Membership starting in 2025. Through LEAP, female amateurs who ...